Ron Lloyd

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 8/25/2008    Last Visited: 8/28/2008  

  A gentamicin surgical implant complements Baxter's surgical portfolio of products for hemostasis and tissue sealing," said Ron Lloyd, vice president and general manager of Baxter's BioSurgery business.

• 
  www.path4.com/press/pressreleases_7.10.07.html - [Cached Version]
  Published on: 7/10/2007    Last Visited: 8/20/2008  

  "The therapeutic benefits of our fibrin sealants have been proven in a wide variety of clinical applications," said Ronald Lloyd, vice president and general manager of Regenerative Medicine at Baxter.

• 
  www.baxterhealth.com/about_baxter/news_room/news_releas - [Cached Version]
  Published on: 8/25/2008    Last Visited: 10/9/2008  

  A gentamicin surgical implant complements Baxter's surgical portfolio of products for hemostasis and tissue sealing," said Ron Lloyd, vice president and general manager of Baxter's BioSurgery business.

• 
  www.asianhhm.com/news/news_archives.asp?NewsID=414 - [Cached Version]
  Published on: 12/17/2007    Last Visited: 9/27/2008  

  Speaking on the same, Ron Lloyd, vice president, Baxter's BioTherapeutics and Regenerative Medicine business, said, "Baxter is pleased about the agreement with Pfizer and FDA approval of this combination hemostasis product."

• 
  seattle.bizjournals.com/austin/stories/2007/07/09/daily - [Cached Version]
  Published on: 7/11/2007    Last Visited: 7/12/2007  

  Austin Ventures, Baxter Healthcare Corp., Path4 Ventures, Spinal Restoration Inc., Gary Sabins, Ronald Lloyd,
  ...
  "The therapeutic benefits of our fibrin sealants have been proven in a wide variety of clinical applications," says Ronald Lloyd, vice president and general manager of Regenerative Medicine at Baxter.

• 
  www.rehabpub.com/press_release.asp?id=10182769 - [Cached Version]
  Published on: 12/17/2007    Last Visited: 12/18/2007  

  "Baxter is pleased about the agreement with Pfizer and FDA approval of this combination hemostasis product," said Ron Lloyd
  
  , vice president of Baxter's BioTherapeutics and Regenerative Medicine business.

• 
  www.rtmagazine.com/press_release.asp?id=10082281 - [Cached Version]
  Published on: 6/20/2007    Last Visited: 6/21/2007  

  "Baxter's new partnerships will broaden the application of TISSEEL in new and investigational applications that are intended to address unmet needs," said Ronald Lloyd
  
  , vice president and general manager of Regenerative Medicine at Baxter.

• 
  austin.bizjournals.com/austin/stories/2007/07/09/daily1 - [Cached Version]
  Published on: 7/11/2007    Last Visited: 10/14/2007  

  "The therapeutic benefits of our fibrin sealants have been proven in a wide variety of clinical applications," says Ronald Lloyd, vice president and general manager of Regenerative Medicine at Baxter.

• 
  Arriva Pharmaceuticals | News | Press Releases - [Cached Version]
  Published on: 2/27/2004    Last Visited: 4/10/2007  

  "Baxter is committed to bringing to market new therapies to address Hereditary Emphysema, where options have been limited," said Ron Lloyd, Vice President, Marketing, Baxter BioScience.

• 
  Baxter Announces FDA Approval of ARTISS Slow-Setting... - [Cached Version]
  Published on: 3/20/2008    Last Visited: 8/14/2008  

  "ARTISS is a safe and effective alternative to staples, reducing discomfort among burn patients requiring skin grafts," said Ron Lloyd, general manager, Baxter's BioSurgery business.

Page:  1 2 3